Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Astrocytic ALKBH5 in stress response contributes to depressive-like behaviors in mice
Cognitive function in obese individuals improves substantially with weight loss alone, but the direct central GLP-1R effects may contribute additional benefit beyond what weight reduction alone would predict
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral semaglutide, made by Novo Nordisk, suggests the former pill may have the edge in reducing blood sugar and weight
Cardiovascular effects: Phase 2 trial data indicate that retatrutide was associated with modest increases in resting heart rate, consistent with observations seen with other GLP-1 receptor agonists
US$ 22.67
US$ 21.42
US$ 20.45
US$ 21.55
